Innovation Premium for Innovative Orphan Drugs in Oncology and Rare Diseases

Published by Mark Nuijten and Stefano Capri, a new concept  Innovation Premium for Innovative Orphan Drugs in Oncology and Rare Diseases in Journal of Market Access & Health Policy.

In this concept we combine health economic and economic valuation theory for assessing the high prices of orphan drugs.

This study shows drug prices based on an innovation premium may be more representative of the actual value of innovation for the society.

Mark Nuijten & Stefano Capri (2020) Pricing of orphan drugs in oncology and rare diseases, Journal of Market Access & Health Policy, 8:1, DOI:10.1080/20016689.2020.1838191

NuijtenPricing_of_orphan_drugs_in_oncology_and_rare_diseases.pdf